Adverse effects after vaccination against SARS-CoV-2 (COVID-19) in Down syndrome adults

Michele Lacerda de Andrade; Laura Uehara; Janaina Ferreira de Moraes; João Carlos Ferrari Corrêa; Fernanda Ishida Corrêa

doi:10.5585/22.2023.23794

Authors

Michele Lacerda de Andrade Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0002-2763-8042
Laura Uehara Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0002-3941-859X
Janaina Ferreira de Moraes Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0002-8267-8557
João Carlos Ferrari Corrêa Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0002-8642-9814
Fernanda Ishida Corrêa Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0001-7321-6257

DOI:

https://doi.org/10.5585/22.2023.23794

Keywords:

Down syndrome, Vaccines, COVID-19, Adverse effects.

Abstract

Introduction: Comorbidities in adults with Down syndrome are common making them a risk group for COVID-19. Thus, vaccinating against COVID-19 becomes necessary, but requires care against possible side effects.
Objective: To investigate possible adverse effects after vaccination against COVID-19 in adults with Down Syndrome (DS).
Methodology: Descriptive study in which ninety-seven adults diagnosed with DS were interviewed using a questionnaire containing seventeen questions related to personal and historical data, and seven questions related to vaccination.
Results: The most applied vaccine was AstraZeneca (94%), Pfizer (4%), and CoronaVac (2%); 74% of the subjects had adverse effects, the most frequent after the first dose being pain at the injection site (65.3%), fever (37.9%), muscle pain (37.8%), malaise (29.5%); in the second dose there was a decrease in these adverse effects; 95% of symptoms disappeared after the first 24 hours following application.
Conclusion: More than half of the individuals interviewed had adverse effects after the application of the first dose of the vaccine, decreasing with the second dose; the most frequent was pain at the site of application.

Downloads

Download data is not yet available.

References

Huang C, Wang Y, Li. X, Ren. L, Zhao. J, Hu. Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lanceta. 2020;(January):19–21.

Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020;35(5):1545–9.

Gómes CC, Rodriguez ÓP, Torné ML, Santaolalla CE, Jiménez JFM, Fernández JG, et al. Clinical Consensus Recommendations Regarding Non-Invasive Respiratory Support in the Adult Patient with Acute Respiratory Failure Secondary to SARS-CoV-2 infection. Arch Bronconeumol. 2020;56:11–8.

Silva AC, Heidemann AM, Cunha AA, Monte ABFO , Monteiro ACDCG, Vian BS, Et Al. Manual De Condutas Assistência Fisioterapêutica No. 2020.

Ministério da Saúde. Manejo Clínico Protocolo da COVID-19 de Manejo Clínico na Atenção Especializada Protocolo da COVID-19. 2020.

Murbe D, Kriegel M, Lange J, Schumann L, Hartmann A, Fleischer M. Aerosol emission of adolescents voices during speaking, singing and shouting. PLoS One. 2021;16(2 February):1–10.

World Health Organization W. Timeline: WHO response COVID-19. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline (acessado em 02/Dez/2020). 2021;2019–21.

GOV.UK. Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine. Medicines & Healthcare products Regulatory Agency. (https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-COVID-19/conditions-of-authorisation-for-pfizerbiontech-COVID-19-vaccine). 2020; Conditions. (Regulamento 174):1–9.

GOV.UK. Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine. Medicines & Healthcare products Regulatory Agency. (https://www.gov.uk/government/publications/regulatory-approval-of-COVID-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-COVID-19-vaccine-astrazeneca). 2020;(Regulamento 174):1–15.

GOV.UK. UK medicines regulator gives approval for first UK COVID-19 vaccine. Medicines & Healthcare products Regulatory Agency. (https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-COVID-19-vaccine). 2020;2020–3.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-rammerstorfer S, et al. Articles Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1 / 2 , single-blind , randomised controlled trial. 2020;467–78.

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. New England Journal of Medicine. 2021;384(23):2187–201.

Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93.

Butantan I. Vacina contra a COVID-19. https://vacinacovid.butantan.gov.br/vacinas. 2021;19:19–20.

Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15(8):967–76.

Zuber PLF, Autran B, Asturias EJ, Evans S, Hartigan-Go K, Hussey G, et al. Global safety of vaccines: Strengthening systems for monitoring, management and the role of GACVS. Expert Rev Vaccines. 2009;8(6):705–16.

WHO. Adverse events following immunization and causality assessment of an adverse event following immunization. Vol. 16, Chinese Journal of Contemporary Pediatrics. 2014. 1–4 p.

Dieudonné Y, Uring-Lambert B, Jeljeli MM, Gies V, Alembik Y, Korganow AS, et al. Immune Defect in Adults With Down Syndrome: Insights Into a Complex Issue. Front Immunol. 2020;11(May):1–7.

Amanzio M, Mitsikostas DD, Giovannelli F, Bartoli M, Cipriani GE, Brown WA. Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. The Lancet Regional Health - Europe. 2022;12:100253.

Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–79.

Raw RK, Rees J, Kelly C, Wroe C, Chadwick DR. Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine. Vaccine. 2021.

Wi YM, Kim SH, Peck KR. Early adverse events between mrna and adenovirus-vectored COVID-19 vaccines in healthcare workers. Vaccines (Basel). 2021;9(8):1–7.